Palouse Capital Management Inc. Buys Shares of 54,374 Sanofi $SNY

Palouse Capital Management Inc. bought a new position in Sanofi (NASDAQ:SNY) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 54,374 shares of the company’s stock, valued at approximately $2,620,000. Sanofi comprises about 1.7% of Palouse Capital Management Inc.’s investment portfolio, making the stock its 22nd largest position.

A number of other large investors have also made changes to their positions in the company. CSM Advisors LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at $18,244,000. Natixis Advisors LLC increased its position in Sanofi by 11.8% in the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock worth $146,952,000 after buying an additional 327,569 shares in the last quarter. XY Capital Ltd purchased a new stake in Sanofi in the third quarter worth about $1,603,000. Regal Partners Ltd raised its stake in shares of Sanofi by 7.1% in the third quarter. Regal Partners Ltd now owns 1,657,539 shares of the company’s stock worth $78,236,000 after buying an additional 109,335 shares during the period. Finally, SageView Advisory Group LLC bought a new position in shares of Sanofi in the third quarter worth about $1,442,000. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SNY shares. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research report on Monday, April 20th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley set a $52.00 target price on shares of Sanofi in a report on Friday, May 1st. Finally, Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $51.00.

Sanofi Trading Down 2.4%

Shares of Sanofi stock opened at $41.63 on Thursday. The firm has a market cap of $100.93 billion, a price-to-earnings ratio of 11.63, a PEG ratio of 1.05 and a beta of 0.35. The business has a 50-day moving average price of $43.84 and a 200-day moving average price of $45.90. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were given a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date was Monday, May 4th. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.